Dostarlimab (Jemperli®) in combination with carboplatin and paclitaxel. HTA ID: 24004

Assessment Status Awaiting full HTA submission from Applicant
HTA ID 24004
Drug Dostarlimab
Brand Jemperli®
Indication Dostarlimab is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 02/02/2024
Rapid review completed 09/02/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dostarlimab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/02/2024
Pre-submission consultation with Applicant 09/04/2024